Tempus AI (TEM) Stock Jumps +70% in a Month: Here's What's Fueling the Rally
Key Takeaways
- Tempus AI shares climbed roughly 70% over the last 30 days, moving from about $41.55 on July 29, 2026, to $70.69 on August 27, 2026.
- The sharpest single move came after a Phase 3 melanoma win from Merck and Moderna, which investors saw as validation of Tempus's pending $1.5 billion acquisition of Personalis.
- Fresh FDA clearances for its xT CDx companion diagnostic and ECG-PH cardiovascular software, plus a higher Wall Street price target, reinforced the advance.
- Over the last quarter, the stock traced a volatile, V-shaped path—sliding into late July before staging a rapid recovery.
Tempus AI (TEM) Company Overview and Market Position
Tempus AI (TEM) is a healthcare technology company that applies artificial intelligence and machine learning to precision medicine. Its business spans two segments: Diagnostics, which includes oncology genomic profiling, hereditary cancer testing, and molecular residual disease (MRD) monitoring, and Data and Applications, which licenses de-identified clinical and molecular data and builds AI models for pharmaceutical partners. Founded by Eric Lefkofsky and listed on Nasdaq, Tempus has positioned itself at the intersection of AI and healthcare. In my view, investors follow the stock closely as a proxy for AI-driven diagnostics and healthcare data monetization.
Tempus AI (TEM) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TEM advanced roughly 70%, from a closing price of $41.55 on July 29, 2026, to $70.69 on August 27, 2026. The move was concentrated in mid-August, when the shares surged more than 20% in a single session following the Merck–Moderna oncology readout.
The last quarter tells a more volatile story. From roughly $51 in late May 2026, the stock first rallied toward $61.60 in early July, then pulled back about 33% to its late-July low near $41.55, and finally rebounded to $70.69 by late August—a net gain of roughly 38% over the period. From what I see, this choppy pattern reflects shifting sentiment across AI and healthcare technology names.
What Drove TEM Stock Price in the Last 30 Days
The dominant catalyst was oncology news rather than a company-specific earnings event. On August 19, 2026, Merck (MRK) and Moderna (MRNA) announced that their Phase 3 INTerpath-001 trial of the personalized mRNA cancer therapy V940 combined with Keytruda met its recurrence-free survival endpoint in melanoma. Because Tempus's pending acquisition of Personalis (PSNL) brings in-house the sequencing platform that has supported the V940 program, investors interpreted the result as validation of the deal, sending TEM up about 24%.
Regulatory momentum added support. Tempus received FDA clearance for Tempus ECG-PH, an AI tool that flags signs of pulmonary hypertension from standard ECGs—its third cardiovascular clearance—and earlier secured FDA approval for its tumor-only xT CDx companion diagnostic, which enables unified Advanced Diagnostic Laboratory Test pricing and an estimated $85 million in annual revenue uplift beginning in 2027. BTIG analyst Mark Massaro also raised his price target on the stock to $80 from $70, citing the sequencing opportunity tied to the cancer-vaccine program. I also ran this through Tickeron's AI Screener to see how TEM compares with other diagnostics names on fundamentals and momentum.
Fundamentals underpinned the advance. In its second-quarter report, Tempus posted revenue of $382.5 million, up 22% year over year, achieved its first quarterly GAAP net profit of $5.6 million, and raised full-year 2026 revenue guidance to $1.595–$1.605 billion.
What Drove TEM Stock Performance Over the Last Quarter
The quarterly trend was shaped by a mix of operational execution and shifting risk appetite. Tempus announced its agreement to acquire Personalis for $1.5 billion in July, positioning the company to internalize MRD testing and next-generation sequencing. During the quarter it also delivered strong second-quarter results, raised guidance, completed a $460 million zero-coupon convertible-note offering, and expanded its data business with agreements including AstraZeneca and BioNTech, while data licensing and modeling revenue grew 36% year over year.
The mid-quarter pullback reflected profit-taking and broader volatility in richly valued AI and healthcare technology stocks, along with investor concerns about dilution and integration risk tied to the Personalis transaction. The August recovery, in turn, was driven by the clinical validation of that acquisition and by a series of regulatory milestones. One thing that stands out is how quickly the narrative shifted—I'm watching closely whether that momentum holds as the deal approaches closing.
TEM Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching the integration of Personalis, a transaction expected to close in late 2026 or early 2027, along with the ramp of MRD testing, which reached roughly 9,000 tests in the second quarter, up 38% sequentially. Reimbursement developments will also matter: the migration of Tempus's solid-tumor DNA portfolio to ADLT pricing, the anticipated FDA decision on its xF liquid biopsy assay in the latter half of 2027, and broader payer coverage could all influence revenue and margins. Competitive dynamics in genomics and diagnostics, including progress from Guardant Health (GH) and Natera (NTRA), and any dilution or financing considerations tied to the acquisition remain key factors for investors to monitor. I've also been checking Tickeron's AI Trend Prediction Engine to track how the model's short-term outlook for TEM evolves alongside these catalysts.
How I Use Tickeron's AI Robots for This Kind of Move
For setups like the one TEM just produced, I like to cross-reference the thesis against automated strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, and its curated Trending AI Robots section surfaces the strategies currently in favor. The bots vary in approach—some lean on short-term momentum, others use longer-horizon or volatility-based logic—so reviewing them helps me compare active strategies rather than relying on a single model.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TEM's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for TEM moved out of overbought territory on September 29, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In 13 of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEM as a result. In 30 of 35 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 16 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 110 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
TEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 49 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (34.722) is very high in comparison to the industry average of (7.432). P/E Ratio (39.298) is within average values for comparable stocks, (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement